Chris Shibutani
Stock Analyst at Goldman Sachs
(0)
# 4605
Out of 5,347 analysts
110
Total ratings
52.38%
Success rate
-16.69%
Average return
Main Sectors:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
PCVX Vaxcyte | Maintains: Buy | 138 100 | 32.51 | 207.6% | 2 | Apr 1, 2025 | |
ERAS Erasca | Maintains: Buy | 4 3 | 1.4 | 114.29% | 7 | Mar 21, 2025 | |
MCRB Seres Therapeutics | Maintains: Sell | 20 15 | 7.08 | 111.86% | 4 | Mar 14, 2025 | |
ALKS Alkermes | Maintains: Strong Buy | 30 32 | 30.61 | 4.54% | 5 | Feb 14, 2025 | |
BNTX BioNTech | Upgrades: Buy | 90 137 | 95.8 | 43.01% | 7 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 30 33 | 10.55 | 212.8% | 3 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 243 302 | 318.42 | -5.16% | 4 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 50 51 | 32.87 | 55.16% | 3 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 160 155 | 155.02 | -0.01% | 3 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 3 4 | 5.13 | -22.03% | 8 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 9 8 | n/a | n/a | 5 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 18 20 | 9.22 | 116.92% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 650 723 | 737.72 | -2% | 6 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 29 26 | 21.61 | 20.31% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 134 153 | 122.95 | 24.44% | 2 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 173 | 186.03 | -7% | 4 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | n/a | n/a | n/a | 4 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 81 69 | 48.3 | 42.86% | 3 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 5 3 | n/a | n/a | 3 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 15 13 | 19.55 | -33.5% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 20 23 | 39.38 | -41.59% | 3 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 117 144 | n/a | n/a | 2 | Jan 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 50 | 1.71 | 2823.98% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 40 52 | 29.64 | 75.44% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 47 60 | 23.46 | 155.75% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 13 18 | 7.58 | 137.47% | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 23 20 | n/a | n/a | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 17 | 2.21 | 669.23% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 90 | n/a | n/a | 1 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | Jul 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | n/a | n/a | n/a | 2 | Jan 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | n/a | n/a | n/a | 3 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | Dec 21, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | n/a | n/a | n/a | 2 | May 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | Mar 24, 2017 |